Transcriptional Profiling of Tofacitinib Treatment in Juvenile Idiopathic Arthritis: Implications for Treatment Response Prediction
Authors' conclusion
Tofacitinib treatment in JIA down-regulated genes in interferon and IL-7 signaling pathways regardless of effectiveness. Furthermore, baseline up-regulation of MAPK signaling may predict poor response to tofacitinib treatment in JIA.
Study context
- Population
- Patients with active juvenile idiopathic arthritis (JIA) treated with open-label tofacitinib60 analysed at week 18
- Participants
- 67 patients
- Comparison
- Week 18 vs baseline gene expression; Poor responders (PRs) vs treatment responders (TRs) at baseline
- Outcome
- Changes in gene expression following tofacitinib treatment (week 18 vs baseline)
- Follow-up
- Week 18
Methodological detailsopen-label tofacitinib, whole-blood transcriptional profiling, differential gene expression and gene ontology overrepresentation analyses
- Open-label tofacitinib
- Whole-blood transcriptional profiling
- Differential gene expression and gene ontology overrepresentation analyses
Main finding
As reported in the abstract
Differential gene expression, week 18 vs baseline, all patients
- Genes with significant differential expression (week 18 to baseline)
- 883
Further findings
Baseline differential expression, PRs vs TRs
- Genes with differential expression
- 663
- Up-regulated: activation of MAPK activity
- P = 9.40 × 10-5
- Up-regulated: myeloid cell development
- P = 8.13 × 10-5
- Up-regulated: activation of GTPase activity
- P = 0.00015
- Up-regulated: organelle transport along microtubules
- P = 0.00021
Original publication
Transcriptional Profiling of Tofacitinib Treatment in Juvenile Idiopathic Arthritis: Implications for Treatment Response Prediction. Arthritis Care Res (Hoboken). Published 27 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →